Skip to main content

Table 1 Comparison of demographic characteristics between early-onset group and late-onset group

From: Increased levels of serum IL-17 and induced sputum neutrophil percentage are associated with severe early-onset asthma in adults

 

All (n = 64)

Early-onset group (n = 32)

Late-onset group (n = 32)

χ2/t

P

Sex

 Male, n (%)

34 (53.1)

18 (56.3)

16 (50)

0.251

0.616

 Female, n (%)

30 (46.9)

14 (43.7)

16 (50)

Age, (years), Mean ± SD

46.22 ± 13.90

40.53 ± 15.39

51.91 ± 9.42

3.566

0.001*

Age onset, (years), Mean ± SD

25.59 ± 17.87

9.78 ± 2.62

41.38 ± 11.26

15.46

0.000*

BMI, (kg/m2), Mean ± SD

23.97 ± 3.50

24.14 ± 3.35

23.82 ± 3.66

0.353

0.725

Length of hospital stay, (days), Mean ± SD

7.41 ± 2.57

7.75 ± 2.77

7.06 ± 2.34

1.072

0.288

Asthma duration, (months), Mean ± SD

221.45 ± 186.14

309.06 ± 199.28

133.84 ± 121.87

4.243

0.000*

Smoking history

 Yes, no quit, n (%)

9 (14.1)

3 (9.4)

6 (18.8)

1.956

0.376

 Yes, quit, n (%)

10 (15.6)

4 (12.5)

6 (18.8)

 No, n (%)

45 (70.3)

25 (78.1)

20 (62.4)

Hormone medication history, n (%)

19 (29.7)

13 (40.6)

6 (18.8)

3.668

0.055

Medication use, n (%)

     

 High dose ICS

54 (84.4)

25 (78.1)

29 (90.6)

1.896

0.168

Family history of asthma, n (%)

25 (39.1)

17 (53.1)

8 (25.0)

5.317

0.021*

ACT score, Median (Q1, Q3)

16.0 (14.0, 19.0)

16.0 (14.0, 18.0)

15.5 (14.0, 19.0)

0.061

0.951

Lung function

 FEV1, (L), Mean ± SD

2.03 ± 0.84

2.21 ± 1.04

1.87 ± 0.58

1.544

0.130

 FEV1%pred, (%), Mean ± SD

68.43 ± 20.55

68.13 ± 23.69

68.70 ± 17.61

0.108

0.915

 FVC%pred, (%), Mean ± SD

87.73 ± 17.29

84.43 ± 18.63

90.71 ± 15.67

1.429

0.158

 FEV1/FVC, (%), Mean ± SD

63.87 ± 11.16

65.90 ± 13.37

62.03 ± 8.50

1.364

0.178

 MEF50%, (%), Mean ± SD

39.05 ± 27.13

46.19 ± 34.87

32.58 ± 15.36

2.004

0.050

 MEF25%, (%), Mean ± SD

29.69 ± 19.14

35.01 ± 25.21

24.86 ± 9.22

2.046

0.048*

 MMEF75/25%, (%), Mean ± SD

34.78 ± 23.38

41.11 ± 30.35

29.04 ± 12.42

2.067

0.043*

Complications

 Sinusitis, n (%)

28 (43.8)

14 (43.8)

14 (43.8)

0.000

1.000

 Allergic rhinitis, n (%)

22 (34.4)

13 (40.6)

9 (28.1)

1.108

0.292

Atopy, n (%)

37 (57.8)

21 (65.6)

16 (50.0)

1.602

0.206

Allergens

 Medicine, n (%)

14 (21.9)

9 (28.1)

5 (15.6)

1.463

0.226

 Dust mites, n (%)

24 (37.5)

17 (53.1)

7 (21.9)

6.229

0.013*

 Blattellagermanica, n (%)

22 (34.4)

13 (40.6)

9 (28.1)

0.931

0.335

 Aspergillus fumigatus, n (%)

9 (14.1)

5 (15.6)

4 (12.5)

0.000

1.000

 Shrimp, n (%)

17 (26.6)

10 (31.3)

7 (21.9)

0.601

0.438

 Dermatophagoides farinae, n (%)

20 (31.3)

14 (43.8)

6 (18.8)

4.325

0.038*

Total IgE, (U/L), Median (Q1, Q3)

254.0 (86.39, 602.35)

319.7 (156.0, 607.8)

179.7 (69.74, 646.5)

0.969

0.332

  1. SD: standard deviation; BMI: body mass index; ACT: asthma control test; Q1: quartile 1; Q3: quartile 3; ICS: Inhaled glucocorticoid; FEV1: forced expiratory volume in 1 s; FEV1%pred: FEV1 percentage of predicted; FVC: forced vital capacity; FVC%pred: FVC percentage of predicted; MEF: maximum expiratory flow; MMEF: maximal mid-expiratory flow
  2. *Represent P < 0.05, suggest statistical significance